LORLATINIB IN ALK-POSITIVE LYMPHOMA PATIENTS REFRACTORY AND PREVIOUSLY EXPOSED TO OTHER TYROSINE KINASE INHIBITORS (SIE 2026) - Oct 6, 2026 - Abstract #DP169; Pres time: Sep 22, 2026; 06:30 PM - 07:30 PM; Location: AREA POSTER; P2 | "Among these, 50–70% achieve durable remis- sion with crizotinib, a first-generation ALK tyrosine kinase inhibitor (TKI), but outcomes after TKI failure remain poor. Lorlatinib induced high and durable response rates with favorable tolerability in R/R ALK-positive lympho- mas. Early combined 18F-FDG PET and RT-PCR assessment may identify patients likely to achieve sustained remission versus those requiring early treatment consolidation."
Clinical • B Cell Lymphoma • Bone Marrow Transplantation • Dyslipidemia • Large B Cell Lymphoma • Lymphoma • Metabolic Disorders • Non-Hodgkin's Lymphoma • ALK • ROS1
|
|
A. Aroldi1,2; F. Cocito1; F. Colombo1,2; A. Ripamonti1,2; E. Bossi1; G. Rindone1; L. Verga1; F. Cavalca1; B. Manghisi1; A. Rapella1,2; S. Bonfanti1,2; B. M. Granelli1,2; E. Scomazzon3; F. Pagni2,4; V. L'Imperio2,4; L. Monaco5; L. Guerra2,5; L. Mussolin6,7; D. Ramazzotti2; R. Chiarle8,9,10; L. Mologni2; R. Piazza1,2; C. Gambacorti-Passerini1,2
|